The contrast agent, simply called Gadobutrol Injection, has been approved by the U.S. Food and Drug Administration and is now available in the United States.
Representative transverse dynamic contrast-enhanced MRI scans in patients in the high (left) and low (right) tertiles of volume of enhancing parenchyma.
A new AI model helped researchers identify a relationship between background parenchyma enhancement on breast MRI exams and breast cancer risk.
Nicholas Smedira, MD, a cardiovascular surgeon with Cleveland Clinic, discusses septal myectomy and the need to improve overall HCM care with new standards and evidence-based guidelines.